On September 12, 2026, the International Society of Urological Pathology (ISUP) will host a “Multidisciplinary Expert Consultation Conference on Precision Biomarker Testing in Bladder and Prostate Cancer“, open to members and non-member clinicians and scientists in pathology, urology, oncology, and related fields. The conference will take place immediately preceding the 38th European Congress of Pathology (ECP 2026) in Stockholm, Sweden, and will be held in person without a hybrid format.

Meeting Objectives:

  1. Review the current landscape and clinical implementation of biomarker testing in bladder and prostate cancer.
  2. Establish standardized, evidence-based recommendations for biomarker testing, interpretation, and reporting.
  3. Define optimal specimen requirements, pre-analytical considerations, and specimen selection strategies for biomarker testing.
  4. Define the role, clinical indications, limitations, and validation requirements of liquid biopsy.
  5. Define the current and future roles of artificial intelligence and digital pathology in biomarker assessment, including workflow integration and quality assurance.
  6. Identify knowledge gaps and research priorities to guide future studies, clinical trials, and guideline development.

 

This Consensus will be Co-Chaired by ISUP members, Dr. Liang Cheng (Providence, RI, USA), and Dr. Geert van Leenders (Rotterdam, Netherlands).

 

Date and Time:  September 12, 2026, 7:30 am – 1:30 pm (Stockholm, Sweden)

Meeting Venue: Grand Hôtel Stockholm (Website: https://grandhotel.se/)

Address: Södra Blasieholmshamnen 8, 103 27 Stockholm, Sweden

 

 

 

Agenda: Details coming soon

 

 
 

Working Group 1: Biomarker Testing in Bladder Cancer

WG 1 Chairpersons: Michelle R. Downes, Antonio Lopez-Beltran

 

WG1 Subgroup 1: FGFR – MIBC and NMIBC

Hikmat Al-Ahmadie (Chair), Arndt Hartmann, Jeffrey S. Ross, David J. McConkey, Dilek Ertoy Baydar, Bas WG van Rhijn, Tianxin Lin

WG1 Subgroup 2: HER2 and other/emerging drug antibody conjugates

Charles Guo (Chair), Mahmut Akgul, Adeboye O. Osunkoya, Isabel Alvarado-Cabrero, Ankur Sangoi, Ashish M. Kamat, Joshua J. Meeks

WG1 Subgroup 3: Immune related biomarkers (PD-L1, MMR, TMB and novel/emerging markers)

Markus Eckstein (Chair), Donna E. Hansel, Toyonori Tsuzuki, Puay Hoon Tan, Eva M. Comperat, Michael C. Cookson, Wassim Kassouf

WG1 Subgroup 4: Preanalytical issues

Maria Raspollini (Chair), Maria S. Tretiakova, Sean R. Williamson, Theodorus van der Kwast, Santosh Menon, Büşra Yaprak Bayrak

WG1 Subgroup 5: Liquid biomarkers (blood and urine)

Joshua I. Warrick (Chair), Lars Dyrskjøt, Bishoy M. Faltas, Hui Ying He, Philippe Spiess, Roger Li

WG1 Subgroup 6: Digital/artificial intelligence

Seema Kaushal (Chair), Francesca Khani, George J. Netto, William Y. Kim, David M. Berman, Shahrokh F. Shariat

Working Group 2: Biomarker Testing in Prostate Cancer

WG2 Chairpersons: Gladell P. Paner, Alessia Cimadamore

 

WG2 Subgroup 1: Preanalytical and postanalytical considerations

Kenneth A. Iczkowski and Glen Kristiansen (Chairs), Katrina Collins, Cristina Magi-Galluzzi, Rodolfo Montironi, Murali Varma, Vishal Rao
 

WG2 Subgroup 2: BRCA1 and 2 and HRR

Steven C. Smith and Jane Nguyen (Chairs), Jiaoti Huang, Daniel W. Lin, Pasquale Rescigno (oncologist), Mark A. Rubin

WG2 Subgroup 3: MSI-H/dMMR/TMB>10

Nancy Greenland and Rafael Jimenez (Chairs), Daniel M. Berney, Holger Moch, Andrea Necchi ), Sara E. Wobker

WG2 Subgroup 4: PI3KCA-AKT-mTOR pathway inhibitors (PTEN) and other chemotherapy-related predictive biomarkers

Tamara Lotan and James G. Kench (Chairs), Thomas W. Flaig, Gianluca Giannarini, Rajal B. Shah, Jeffrey So

WG2 Subgroup 5: Other potential or emerging tumor-agnostic biomarkers (e.g., ADCs, DLL3, PD-L1)

Aiman Haider and Angelo M. DeMarzo (Chairs), Mahul B. Amin, Anders Bjartell, Arul M. Chinnaiyan, Herbert Lepor, Anandi Lobo, Daniel E. Spratt

WG2 Subgroup 6: Liquid biopsy (e.g., ctDNA, CTCs) and digital/artificial intelligence

Fiona Maclean and Turki Al-Hussain (Chairs), Ni Chen, Michael C. Haffner, Anil V. Parwani, Chin Lee Wu

 
 

 

General questions: Katrina Collins  katrinacollinsmd@gmail.com and/or Nancy Greenland nancy.greenland@ucsf.edu

Partially sponsored by: